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Study Design and Method
Sample preparation
PTHrP (1-36) Assay Validation
Aims and Objectives
 To review the use of PTH (1-34) measurements in drug development studies, and in the diagnosis of 
patients with PHP.
 To highlight the potential use of measurement of PTHrP (1-36) using our LC-MS/MS method for 
measurement of intact PTHrP (1-36), intact PTH (1-34) and its respective oxidized forms 
simultaneously. Figure (2). Typical calibration curve for hPTHrP (1-36) spiked
into charcoal-stripped human EDTA plasma. R2 value is
0.968.
 Linear calibration curve from 
25 to 2000 pg/mL
 Typical linear regression 
analysis (r2 = 0.968)
 Lower limit of Quantification 
(LLoQ): 25 pg/mL
 Lower limit of detection 
(LLoD): 2.5 pg/mL
Imprecision :
Stock of hPTHrP (1-36) calibrators and controls were prepared in our laboratory by spiking high purity
(>98.0%) recombinant hPTHrP (1-36) (Creative BioMart, NY 11967, USA) in charcoal-stripped rat EDTA
plasma. Intra-imprecision profile was generated by running all QC samples 10 times within a single run,
while inter-imprecision profile was generated by repeated measurements (n=10) of all QCs over a
period of a month.
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Recovery efficiency:
Teriparatide, a recombinant human PTH (1-34) is an osteoanabolic agent for treatment of osteoporosis.
PTH (1-34) can also be used a replacement therapy in hypoparathyroidism and to accelerate fracture
healing. Abaloparatide, PTHrP (1-34) analogue is a novel anabolic drug for treatment of osteoporosis.
Measurement of plasma PTH (1-34) has also been used to assess response to PTH in conditions such as
pseudohypoparathyroidism (PHP) (Ellsworth-Howard test (EHT)).
Figure (1). Chromatograms showing the
separation of human PTH (1-34) and its
respective single- and double-oxidised
forms from human PTHrP (1-36) as well as
the internal standard rat PTH (1-34)
fragment.
Analytes separation and detectionSample Collection
 PTH (1-34) was analysed in
EDTA plasma obtained from
human subjects given either
single subcutaneous (sc)
injection of 20 µg
Teriparatide (n=10) or 0.69
mg (n=5), 2.07 mg (n=10) oral
PTH (1-34) (EnteraBio).
 Baseline samples were taken
immediately before drug
administration.
QC level 
(pg/mL)
Inter-assay imprecision (n=10) Intra-assay imprecision (n=10)
Mean SD SE %CV %Accuracy Mean SD SE %CV %Accuracy
QC1 (50) 51.9 5.6 0.6 10.8 100 52.5 6.5 0.7 12.4 100
QC2 (100) 97.5 11.5 1.2 11.8 100 101.5 10.0 1.0 9.9 100
QC3 (200) 211.9 16.8 1.7 7.9 100 203.5 15.6 1.6 7.7 100
QC4 (800) 803.9 47.4 4.7 5.9 100 822.5 57.3 5.7 7.0 100
Endogenous PTHrP (1-
36) (pg/mL)
Spiked (pg/mL) Expected concentration 
(endogenous + spiked) 
(pg/mL)
Mean (±SEM)
measured PTHrP (1-
36) (pg/mL)
%Recovery
Mean (%CV)
50 50 100 113.7 (±7.7) 113.7 (±27.1)
50 500 550 567.4 (±5.1) 103.2 (±3.6)
400 50 450 435.3 (±9.8) 96.7 (±9.6)
400 500 900 951.5 (±15.5) 105.7 (±6.5)
800 50 850 877.4 (±22.4) 103.2 (±10.2)
800 500 1300 1297.1 (±20.6) 99.8 (±6.4)
The Use of PTH (1-34) Measurement in Pharmacokinetics Studies
Figure (5). Concentration-time profiles of participants treated
with 20 µg teriparatide, and oral PTH (1-34) (0.69 and 2.07 mg).
Time course of samples collection was 0-300 minutes. Each
point represent (mean±SEM) of plasma PTH (1-34)
concentration.
Figure (6). Box and Whisker representation of Cmax obtained for standard
Forsteo® injection and oral (0.69 and 2.07 mg) administration. Asterisk
represents outlier (Cmax= 626.9 pg/mL) recorded for one participant given
2.07 mg oral PTH (1-34) dose. Forsteo’s Cmax is bracketed by the two oral
doses Cmax . The Cmax of oral treatment is proportional to dosage.
The Use of PTH (1-34) Measurement in the Diagnosis of PHP
Conclusions
Figure (7). Ellsworth-Howard test results on a patient
suspected of PHP. Note the blunted plasma cAMP
response and the lack of urine cAMP excretion
despite the sharp increase in plasma PTH (1-34) level.
Phospateuric response is also deficient.
PHP disorders are characterized by
impaired signalling of various
hormones (mainly PTH) that activate
cAMP-dependent pathways via Gsα
protein. Ellsworth-Howard test or
PTH loading test has been used
traditionally to confirm PHP.
Measurement of serum and urinary
cAMP concentrations after the
injection of exogenous PTH plus PO4
measurement confirmed the
diagnosis of PHP type 1 (PHP1), in
which a blunted cAMP response is
observed, from PHP type 2 (PHP2) in
which the cAMP response to PTH is
conserved but the phosphaturic
response is deficient.
Our method for measurement of non-oxidised and oxidised forms of PTH (1-34) as well as for PTHrP (1-36) may: 
1) offer new insights into the physiology and pathophysiology of PTH
2) help investigate the therapeutic use/efficacy of osteoanabolic agents
3) help in development of combination therapy with other anti-resorptive/ anti-remodelling agents.
.
Oxidation of PTH (1-34) and PTHrP (1-36)
 Oxidation of the sulphur atom in methionine residues by peroxides is one of the major degradation
pathways of therapeutic peptides. PTH (1-34) contains two methionine groups at position 8 (Met8) and
position 18 (Met18).
 Three oxidized PTH (1-34) products were isolated, namely Met8 sulfoxide, Met18 Sulfoxide, and both
positions Met Sulfoxide
 Oxidation of the methionine residues causes a change in the secondary structure of PTH (1-34),
especially oxidation of Met8. The change in the secondary structure is greater when both methionine
residues are oxidised.
 Double oxidized forms of PTH (1-34) possess reduced biological activity, which consequently reflected
on the potency of the treatment
 In contrast to human PTH (1-34), human PTHrP (1-36) peptide does not contain methionine residue in
its structure. We found that PTHrP (1-36) is not oxidised by hydrogen peroxide (H2O2).
 Our data showing that oxidation contributes by (23.9 ± 6.1%) to bias between our LC-MS/MS method for
PTH (1-34) and immunoassay results.
 Due to the absence of methionine residues in human PTHrP (1-36) and analogues of hPTHrP (1-34) such
as Abaloparatide they are resistant to oxidation, hence this may explain some of the difference in
efficacy observed in Abaloparatide preclinical/clinical studies. However, further investigations are
required to confirm this possibility.
Figure (3). MS spectrum of human PTH (1-34) (MW = 4117.8 D) before
and after 40 and 60 min oxidation with H2O2. A & D represent +7 and +6
charged state of non-oxidised hPTH (1-34) respectively. B & E represent
+6 and +7 charged state of hPTH (1-34) oxidised at Met 8 or Met 18
respectively (single-oxidised form with an increase of 16 mass units). C &
F represent +6 and +7 charged state of hPTH (1-34) oxidised at both Met
8 and Met 18 respectively (double-oxidised form with an increase of 32
mass units)
 Post-dose blood samples were collected every 15 minutes for
two hours then hourly for three hours (time course 0-300
min).
 Ellsworth-Howard test procedure was carried on a patient
with suspected PHP.
Urine cAMP and PO4 were analysed on samples voided every
30 min for 3 hours post PTH (1-34).
Figure (4). MS spectrum of human PTHrP (1-36) (MW= 4266.5 D) before
and after 60 and 120 min oxidation with H2O2. A, B and C represents +7,
+6, and +5 charged states precursor species of hPTHrP (1-36). No peaks
for oxidised forms of PTHrP (1-36) observed even after 2 h oxidation
with 0.1 M H2O2 due to absence of Methionine residues in its structure.
Table: PK parameters for PTH (1-34) of 20 µg subcutaneous
Forsteo® injection and oral (0.69 and 2.07 mg) administration.
Treatment N
Cmax (pg/mL)
(Geometric 
mean ± SEM)
AUC0-last
(pg.h/mL)
(Geometric 
mean ± SEM)
Tmax (min)
(Geometri
c mean ±
SEM)
T1/2 (h)
(Geometric 
mean ± SEM)
Forsteo® 20µg 
sc injection
10 124.5 ± 21.3 105.7 ± 9.3 16.0 ± 2.5 37.7 ± 6.8
Oral 0.69 mg 
hPTH (1-34)
5 56.2 ± 27.4 11.5 ± 7.4 14.7 ± 1.4 11.3 ± 4.8
Oral 2.07 mg
hPTH (1-34)
10 267.8 ± 43.0 109.0 ± 19.2 20.8 ± 1.0 12.6 ± 2.6
